Two and a half years into his tenure as Teva’s CEO, Richard Francis is breaking down the strategy that’s powered the company through nine consecutive quarters of growth.

On this week’s episode of "The Top Line," Fierce Pharma’s Fraiser Kansteiner sits down with Francis to talk about the progress made so far on Teva’s “Pivot to Growth” strategy and what comes next. They dig into the strategies behind the company’s chief commercial medicines, its pipeline darlings and the way Teva’s generic and biosimilar backbone is expected to evolve through the end of the decade. 

To learn more about the topics in this episode: 

• As Austedo, Ajovy and Uzedy gain steam, Teva banks on $5B-plus in 2030 innovative drug sales
• Teva plots thousands of job cuts as restructuring drive enters 'acceleration' phase
• Teva taps Matthew Shields to oversee manufacturing and supply division amid company revamp

This week's episode is sponsored by Cencora. 

See omnystudio.com/listener for privacy information.